Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases
Avalyn Pharma Inc. focuses on inhaled and nebulized therapies for idiopathic pulmonary fibrosis and broader interstitial lung diseases, with attention to progressive forms of fibrosing lung disease.
- Idiopathic pulmonary fibrosis (IPF)
- Interstitial lung disease (ILD)
- Progressive fibrosing lung disease
- Progressive pulmonary fibrosis (PPF)
The sponsor’s clinical work centers on lung scarring disorders where preserving respiratory function is a major therapeutic goal.
Antifibrotic Therapy
The company’s research portfolio includes antifibrotic medicines delivered by inhalation, with studies examining their role in managing chronic fibrotic lung conditions.
- Pirfenidone solution for inhalation
- Nintedanib solution
- Inhaled antifibrotic treatment
- Long-term tolerability
These programs reflect a therapeutic interest in treatments designed for direct pulmonary delivery in fibrosing airway and parenchymal disease.
Pulmonary Function and Disease Progression
Avalyn Pharma’s studies examine outcomes tied to lung function and progression of fibrotic disease, particularly in patients with worsening respiratory impairment.
- Respiratory function preservation
- Disease progression in PPF
- Functional outcomes in IPF
- Chronic fibrosing lung disorders
The trial portfolio is directed toward conditions where slowing decline in pulmonary capacity is clinically important.
Regulatory Access and Ongoing Treatment Continuation
The sponsor also supports studies that maintain patient access to investigational inhaled therapies for ILD and IPF during periods of continued clinical need.
- Open-label extension
- Continued treatment access
- Safety monitoring
- Therapy tolerability
Its research activity is concentrated in respiratory medicine, with a strong emphasis on fibrotic lung disease management.
